Trials / Conditions / Ann Arbor Stage III Follicular Lymphoma

Ann Arbor Stage III Follicular Lymphoma

6 registered clinical trials studyying Ann Arbor Stage III Follicular Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma NCT06442475	University of Washington	Phase 2
Recruiting	Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphom NCT06471738	Chinese PLA General Hospital	Phase 2
Active Not Recruiting	Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymph NCT04450173	University of California, Davis	Phase 2
Active Not Recruiting	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Ly NCT04323956	Mayo Clinic	Phase 1
Active Not Recruiting	Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas NCT03198026	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Completed	Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage NCT02532257	M.D. Anderson Cancer Center	Phase 2